Literature DB >> 29870139

Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.

George M Burslem1, Philipp Ottis1, Saul Jaime-Figueroa1, Alicia Morgan2, Philipp M Cromm1, Momar Toure1, Craig M Crews1,3.   

Abstract

The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years. Recently, their use as E3 ligase recruiting elements for small-molecule-induced protein degradation has led to a resurgence in interest in IMiD synthesis and functionalization. Traditional IMiD synthesis follows a stepwise route with multiple purification steps. Herein we describe a novel one-pot synthesis without purification that provides rapid access to a multitude of IMiD analogues. Binding studies with the IMiD target protein cereblon (CRBN) reveals a narrow structure-activity relationship with only a few compounds showing sub-micromolar binding affinity in the range of pomalidomide and lenalidomide. However, anti-proliferative activity as well as Aiolos degradation could be identified for two IMiD analogues. This study provides useful insight into the structure-degradation relationships for molecules of this type as well as a rapid and robust method for IMiD synthesis.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cereblon; condensation reactions; imides; immunomodulatory drugs; protein degradation

Mesh:

Substances:

Year:  2018        PMID: 29870139      PMCID: PMC6291207          DOI: 10.1002/cmdc.201800271

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  27 in total

Review 1.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 2.  Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.

Authors:  Martha Q Lacy; S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2010-02       Impact factor: 10.047

3.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

Authors:  Daniel P Bondeson; Blake E Smith; George M Burslem; Alexandru D Buhimschi; John Hines; Saul Jaime-Figueroa; Jing Wang; Brian D Hamman; Alexey Ishchenko; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

4.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

Authors:  Jing Lu; Yimin Qian; Martha Altieri; Hanqing Dong; Jing Wang; Kanak Raina; John Hines; James D Winkler; Andrew P Crew; Kevin Coleman; Craig M Crews
Journal:  Chem Biol       Date:  2015-06-04

5.  Structure-activity relationship studies of thalidomide analogs with a taxol-like mode of action.

Authors:  Bulbul Pandit; Zhigen Hu; Somsundaram N Chettiar; Jennifer Zink; Zili Xiao; Jonathan P Etter; Deepak Bhasin; Pui-Kai Li
Journal:  Bioorg Med Chem Lett       Date:  2013-10-04       Impact factor: 2.823

6.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Authors:  K Dredge; J B Marriott; C D Macdonald; H-W Man; R Chen; G W Muller; D Stirling; A G Dalgleish
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

7.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

8.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

9.  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

Authors:  Bing Zhou; Jiantao Hu; Fuming Xu; Zhuo Chen; Longchuan Bai; Ester Fernandez-Salas; Mei Lin; Liu Liu; Chao-Yie Yang; Yujun Zhao; Donna McEachern; Sally Przybranowski; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2017-03-24       Impact factor: 7.446

10.  Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).

Authors:  Nicola E A Chessum; Swee Y Sharp; John J Caldwell; A Elisa Pasqua; Birgit Wilding; Giampiero Colombano; Ian Collins; Bugra Ozer; Meirion Richards; Martin Rowlands; Mark Stubbs; Rosemary Burke; P Craig McAndrew; Paul A Clarke; Paul Workman; Matthew D Cheeseman; Keith Jones
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

View more
  10 in total

1.  Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.

Authors:  Saul Jaime-Figueroa; Alexandru D Buhimschi; Momar Toure; John Hines; Craig M Crews
Journal:  Bioorg Med Chem Lett       Date:  2019-12-13       Impact factor: 2.823

2.  On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.

Authors:  Christopher Heim; Samuel Maiwald; Christian Steinebach; Matthew K Collins; Jonathan Strope; Cindy H Chau; William D Figg; Michael Gütschow; Marcus D Hartmann
Journal:  Biochem Biophys Res Commun       Date:  2020-12-10       Impact factor: 3.575

3.  Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.

Authors:  Jaeki Min; Anand Mayasundari; Fatemeh Keramatnia; Barbara Jonchere; Seung Wook Yang; Jamie Jarusiewicz; Marisa Actis; Sourav Das; Brandon Young; Jake Slavish; Lei Yang; Yong Li; Xiang Fu; Shalandus H Garrett; Mi-Kyung Yun; Zhenmei Li; Stanley Nithianantham; Sergio Chai; Taosheng Chen; Anang Shelat; Richard E Lee; Gisele Nishiguchi; Stephen W White; Martine F Roussel; Patrick Ryan Potts; Marcus Fischer; Zoran Rankovic
Journal:  Angew Chem Int Ed Engl       Date:  2021-11-16       Impact factor: 15.336

Review 4.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

5.  De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.

Authors:  Christopher Heim; Dimanthi Pliatsika; Farnoush Mousavizadeh; Kerstin Bär; Birte Hernandez Alvarez; Athanassios Giannis; Marcus D Hartmann
Journal:  J Med Chem       Date:  2019-07-12       Impact factor: 7.446

6.  Targeting oncoproteins with a positive selection assay for protein degraders.

Authors:  Vidyasagar Koduri; Leslie Duplaquet; Benjamin L Lampson; Adam C Wang; Amin H Sabet; Mette Ishoey; Joshiawa Paulk; Mingxing Teng; Isaac S Harris; Jennifer E Endress; Xiaoxi Liu; Ethan Dasilva; Joao A Paulo; Kimberly J Briggs; John G Doench; Christopher J Ott; Tinghu Zhang; Katherine A Donovan; Eric S Fischer; Steven P Gygi; Nathanael S Gray; James Bradner; Jeffrey A Medin; Sara J Buhrlage; Matthew G Oser; William G Kaelin
Journal:  Sci Adv       Date:  2021-02-05       Impact factor: 14.957

Review 7.  Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs.

Authors:  Shanique Alabi; Craig Crews
Journal:  J Biol Chem       Date:  2021-04-08       Impact factor: 5.157

Review 8.  Discovery of E3 Ligase Ligands for Target Protein Degradation.

Authors:  Jaeseok Lee; Youngjun Lee; Young Mee Jung; Ju Hyun Park; Hyuk Sang Yoo; Jongmin Park
Journal:  Molecules       Date:  2022-10-02       Impact factor: 4.927

Review 9.  E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.

Authors:  Aleša Bricelj; Christian Steinebach; Robert Kuchta; Michael Gütschow; Izidor Sosič
Journal:  Front Chem       Date:  2021-07-05       Impact factor: 5.221

10.  Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations.

Authors:  Mélissanne de Wispelaere; Guangyan Du; Katherine A Donovan; Tinghu Zhang; Nicholas A Eleuteri; Jingting C Yuan; Joann Kalabathula; Radosław P Nowak; Eric S Fischer; Nathanael S Gray; Priscilla L Yang
Journal:  Nat Commun       Date:  2019-08-01       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.